Start-Up Previews (04/2008)
Executive Summary
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Nanotechnology, a Balm for the Challenges of Drug Delivery," features profiles of BIND Biosciences, Liquidia Technologies, Nanolymf, Tempo Pharmaceuticals, and TransGenex Nanobiotech. Plus these Start-Ups Across Health Care: Breathe Technologies, Crospon, and InterMed Discovery.
You may also be interested in...
Crospon Ltd.
New imaging technology employed through a therapeutic endoscope provides the most relevant information to diagnose gastroesophageal reflux disease (GERD), according to its manufacturer, Crospon. Furthermore, the Irish start-up says its novel EndoFLIP (endoscopic functional lumen imaging probe) technology can be used to assist in GERD surgeries and to assess the results.
Breathe Technologies Inc.
The developers of a miniature, wearable ventilator for people with severe respiratory disorders view their product as the iPod of ventilators. Breathe Technologies aims to commercialize the first truly ambulatory ventilator. The company believes its innovative technology will fill an unmet need for patients with severe ventilatory insufficiency, both in the hospital setting and in the home.
TransGenex Nanobiotech Inc.
TransGenex Nanobiotech is taking a multi-pronged approach to building a nanotechnology company. In the short term, the company is generating revenue from sales of its custom nanoparticles and its Nanogene reagents that can be used to deliver genes to cells. It is also using its technology to develop diagnostic platforms, especially for lung and ovarian cancer. Finally, TransGenex plans to develop its own novel drug candidates. It's focusing first on products with anti-inflammatory properties, which could find application in asthma as well as several cancers.